Showing results excluding:
  • pl.investing.com

All Results

  1. SYNNEX TECHNOLOGY INTERNATIONAL CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS JUNE 30, 2024, DECEMBER 31, 2023 AND JUNE 30, 2023 (Expressed in thousands of New Taiwan dollars) The accompanying notes are an integral part of these consolidated financial statements. ~8~ June 30, 2024 December 31, 2023 June 30, 2023
  2. November, 2024 2024 Q3 & YTQ Results SYNNEX TECH. INTL. CORP. P2 SYNNEX Confidential IMPORTANT NOTICE Synnex'sstatements of its current expectations provided herein are forward-looking. These statements are subject to risks and uncertainties that might cause significant deviations
  3. marketscreener.com

    May 14, 2024Synnex Public Company Limited reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was THB 9,605.24 million compared to THB...
  4. Nov 6, 2024TWSE:2347 Earnings and Revenue Growth November 6th 2024. All figures shown in the chart above are for the trailing 12 month (TTM) period. Synnex Technology International EPS Beats Expectations, Revenues Fall Short. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) exceeded analyst estimates by 4.7%.
  5. Nov 14, 2024Znormalizowana EBITDA Synektika w IV kw. roku finansowego 2023/2024 wyniosła 35,2 mln zł i była o 7 proc ... by nowy rok finansowy w naszym wykonaniu stał m.in. pod znakiem dalszego umacniania ...
  6. synnexgroup.com

    India Insurance Summit & Awards 2024 is the premier Physical summit of our annual property IISA by Synnex Group. Which brings together innova... Register. Register. NPL & Debt Restructuring Excellence 2025. Thailand 11-14 Mar 2025 The credit market in Asia, Africa, and the Middle East has been growing rapidly in recent years, and the field is ...
  7. Nov 18, 202412 Wyniki Q4 2023 r. fin. | Prezentacja inwestorska 12 Sprzęt medyczny i rozwiązania IT Dynamiczny wzrost przychodów i zysków 41% wzrost przychodów, rdr., w I-IV kw. 2023 roku finansowego, do 579,7 mln PLN 45% wzrost znormalizowanej EBITDA w I-IV kw. 2023 r. fin., do 144,0 mln PLN 385,8 mln PLN przychodów ze sprzedaży sprzętu medycznego ...
  8. Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX